ADOCIA: insider trades · France · AMF

About ADOCIA

Adocia is a French clinical-stage biotechnology company listed on Euronext Paris under ticker ADOC and ISIN FR0011184241. Founded in 2005 in Lyon by Gérard Soula and his two sons Olivier and Rémi, the company was built around a clear mission: to develop “innovative medicines for everyone, everywhere.” Its headquarters are located in Lyon, France, and the company employs around 80 people. Adocia has established itself as a specialist in metabolic diseases, with a particularly strong focus on diabetes and obesity. The company’s core business is the design of innovative formulations for already-approved peptides and proteins, supported by proprietary technology platforms and a strong intellectual property strategy. Its most advanced platform, BioChaperone®, is designed to improve the solubility, stability, enzymatic protection, and therapeutic performance of difficult-to-formulate molecules. The platform has been used in more than 30 clinical trials, ranging from Phase 1 to Phase 3, and Adocia has developed more than 800 BioChaperone compounds over time. The company’s model is to address unmet medical needs, establish human proof-of-concept, and then unlock value through licensing and partnership agreements. Adocia’s portfolio spans several strategic programs. In diabetes, BioChaperone Lispro is an ultra-rapid insulin formulation intended to improve glycemic control. The company retains development rights in many territories, including the United States, Europe, Japan, and Latin America. Adocia is also developing next-generation peptide combinations for obesity, particularly GLP-1 / amylin combinations, as well as AdOral Sema, an oral semaglutide formulation. Other programs such as M1Pram and AdoXLong reflect the company’s ambition to broaden its pipeline with more convenient, longer-acting, or more differentiated treatment options. From an operational and geographic standpoint, Adocia remains a mid-sized biotech centered in Lyon but oriented toward global markets through partnerships. The company has signed licensing or collaboration agreements with international pharmaceutical players, which is consistent with its strategy of monetizing innovation after clinical validation. In 2025-2026, Adocia strengthened its financial structure through several fundraising transactions and stated that its cash position and recent financing extend its funding horizon to the beginning of Q2 2027. This combination of breakthrough science, a focused metabolic pipeline, and international partnering makes Adocia a notable French biotech name in the diabetes and obesity space.